SAN FRANCISCO, July 11, 2018 /PRNewswire/ — Hagens Berman Sobol Shapiro LLP alerts investors in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to the firm’s investigation of possible securities law violations. If you purchased or otherwise acquired ACADIA securities before July 9, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
On July 9, 2018, the Southern Investigative Reporting Foundation published a report concluding that ACADIA improperly promoted the faulty illusion that the Company’s core product received FDA approval like any other drug.
This report drove the price of ACADIA shares down $1.21, or almost 7%, to close at $16.63 that day.
“We’re focused on investors’ losses and on the Foundation’s accusations which, if true, could mean ACADIA and senior management misled investors,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding ACADIA should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email ACAD@hbsslaw.com.
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 80+ attorneys in 10 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Reed Kathrein, 510-725-3000
View original content with multimedia:http://www.prnewswire.com/news-releases/hagens-berman-alerts-investors-in-acadia-pharmaceuticals-inc-acad-to-the-firms-investigation-of-possible-disclosure-violations-300679713.html
SOURCE Hagens Berman Sobol Shapiro LLP